The Hickory Algorithm
Heart disease is the #1 cause of death in women. Understand your risk.
Why Your Heart Attack Risk Quietly Rises in Perimenopause
Heart disease is the leading cause of death in women. Most of the damage starts before anyone is paying attention.
Heart disease isn’t a man’s problem that women occasionally get. It’s the number one killer of women in the United States. It kills more women than all cancers combined, including breast cancer. And yet most women I see in their 40s and early 50s are not thinking about their hearts. They’re thinking about hot flashes, sleep, mood, periods that have gone unpredictable. The heart barely comes up.
That gap in awareness has consequences. The years of perimenopause, which can span a decade before the final menstrual period, are the years when the cardiovascular system is undergoing real, measurable change. Not because aging is catching up with you, but because of something specific: estrogen is leaving.
Understanding what estrogen was doing for your heart, and what happens when it starts to go, is one of the more important things a woman in midlife can know.
What Estrogen Has Been Doing for Your Heart
For your entire reproductive life, estrogen has been quietly doing cardiovascular work. It isn’t only a reproductive hormone. It acts directly on the lining of your blood vessels, on your liver’s handling of cholesterol, on inflammation, and on the muscle of the heart itself.
Specifically, estrogen promotes the production of nitric oxide in the endothelium, the thin tissue that lines every blood vessel in your body. Nitric oxide keeps vessels relaxed, flexible, and responsive to changes in blood flow. Estrogen also helps keep LDL cholesterol from oxidizing, which is the process that transforms it into the inflammatory, plaque-building version that damages arterial walls. It maintains a favorable balance between HDL and LDL. It suppresses inflammatory signals that accelerate atherosclerosis. It helps vessels dilate when they need to.
This is why premenopausal women have significantly lower rates of heart disease than men the same age. The incidence of coronary heart disease in women lags behind men by about 10 years. Heart attack and sudden cardiac death lag by closer to 20 years. That protection is largely estrogen-dependent. Once estrogen declines at menopause, women’s age-specific cardiovascular risk becomes two to six times higher than it was during the premenopausal years. (Cancer Journal, USC Keck School of Medicine, 2022; Framingham Heart Study data)
That’s not a slow, gradual erosion. It’s a meaningful acceleration in risk that tracks the hormonal transition.
When the Changes Actually Begin
Here’s the part most women don’t know: the cardiovascular changes don’t start at menopause. They start in perimenopause, often years before the final menstrual period, and sometimes before symptoms like hot flashes or irregular cycles are even obvious.
The Study of Women’s Health Across the Nation, known as SWAN, followed thousands of women longitudinally through the menopausal transition and documented what happens to the cardiovascular system in real time. The findings are striking. Within the one-year window surrounding the final menstrual period, women experienced significant rises in total cholesterol, LDL cholesterol, and apolipoprotein-B. These changes tracked the hormonal transition directly, not simply the passage of time.
Other SWAN data showed that as estrogen levels fell, protective HDL cholesterol began to lose some of its effectiveness. Even when HDL numbers remained in a normal range, the lipoprotein particles themselves changed character, becoming less protective. Meanwhile, LDL particles shifted toward smaller, denser forms that are more prone to oxidation and more dangerous to arterial walls.
A 2023 scientific statement from the American Heart Association described perimenopause as a pivotal phase in women’s cardiovascular trajectory. Researchers found evidence of endothelial dysfunction, increased arterial stiffness, fat accumulation around the heart, and early atherosclerotic changes beginning during the transition itself, independently of chronological age. The groundwork for future cardiovascular events is laid before menopause is complete.
There is also a specific detail worth noting about FSH, the hormone that rises sharply during perimenopause as the ovaries become less responsive. Independent of estrogen levels, elevated FSH has been shown to stimulate cholesterol production in the liver. This means that even in the early perimenopausal years, when estrogen hasn’t yet fully declined, rising FSH is already pushing cholesterol numbers in the wrong direction.
Visceral fat also increases during perimenopause, independent of changes in overall body weight. Fat deposited around internal organs, including directly around the heart, produces inflammatory cytokines that damage vessels and accelerate atherosclerosis. This is not the same as subcutaneous fat under the skin, and it doesn’t respond well to the same interventions.
Why Women’s Heart Attacks Are So Often Missed
Even when cardiovascular disease does develop, women frequently don’t receive the same quality of diagnosis and care as men. This is not a small problem. Research from the Agency for Healthcare Research and Quality found that women are nearly twice as likely as men to receive an incorrect diagnosis after a heart attack. Women under 55 are seven times more likely than men to be sent home from the emergency room without appropriate cardiac testing.
Part of this is symptom recognition. The classic heart attack presentation, crushing chest pain radiating down the left arm, is more common in men. Women having a heart attack are more likely to experience jaw or neck pain, nausea, shortness of breath, extreme fatigue, dizziness, or something that feels like heartburn. These get attributed to anxiety, gastrointestinal problems, or stress. A 2020 study in Circulation: Cardiovascular Quality and Outcomes found that women, especially women under 55, show a wider variety of symptom combinations than men, making the presentation harder for providers trained on male-centered diagnostic frameworks to recognize.
A study using video vignettes with 128 physicians found that when identical cardiac symptoms were presented in a middle-aged female patient versus a male patient, physicians were significantly less certain of the diagnosis for the woman and more likely to attribute her symptoms to a gastrointestinal or mental health cause. Women were twice as likely as men to be given a mental health diagnosis as the most probable explanation. This wasn’t explained by physician gender, race, or experience level. It was systematic. (PMC/Journal of General Internal Medicine, 2010)
The downstream consequences of delayed or missed diagnosis are severe. Women who have heart attacks have worse outcomes than men. They are more likely to die within the first year, more likely to develop heart failure, more likely to have a second cardiac event within five years. The misdiagnosis gap doesn’t just cause frustration. It costs lives.
What Is Actually Happening to Your Arteries
Atherosclerosis is the buildup of plaque inside arterial walls. It’s not a sudden event. It’s a decades-long process that begins quietly and becomes clinically significant over time. The menopausal transition accelerates it in ways that standard annual exams often don’t capture.
Estrogen normally supports re-endothelialization, the repair of small injuries to arterial lining before they can become entry points for plaque. When estrogen declines, this repair process slows. Smooth muscle cells in arterial walls proliferate more easily. Inflammatory cytokines accumulate. LDL oxidizes more readily. The vessel becomes less able to dilate in response to demand. All of this happens at the cellular level, often without symptoms, for years before anything shows up on a standard lipid panel.
A standard cholesterol panel, which most women receive annually, measures total cholesterol, LDL, HDL, and triglycerides. This misses important dimensions of cardiovascular risk in perimenopausal women. Markers like high-sensitivity CRP (hsCRP), which measures vascular inflammation, the triglyceride-to-HDL ratio, which reflects insulin resistance and small dense LDL particle burden, fasting insulin, and lipoprotein(a) give a more complete picture. A 2024 paper in the Journal of the American College of Cardiology identified Lp(a) as markedly more atherogenic than standard LDL. Estrogen suppresses Lp(a). When estrogen falls at menopause, Lp(a) rises.
If you had a standard lipid panel last year and everything looked “fine,” that doesn’t mean your cardiovascular risk hasn’t changed. Perimenopause can shift the picture substantially in a short period of time, and the standard panel doesn’t measure everything that matters during this transition.
What You Can Do, and What the Research Actually Says
Exercise is the most evidence-based intervention available
Aerobic exercise, particularly the kind that elevates your heart rate into a moderate-intensity zone for sustained periods, is the single most powerful modifiable factor in cardiovascular risk. It improves endothelial function, reduces inflammation, lowers LDL, raises HDL, reduces visceral fat, and improves insulin sensitivity. A meta-analysis cited in the AHA’s 2020 scientific statement on menopause and cardiovascular disease found that physical activity during the menopausal transition was associated with meaningfully lower cardiovascular risk. The effect wasn’t modest.
Resistance training contributes as well, particularly through its effects on insulin sensitivity, body composition, and blood pressure. The combination of both types of exercise appears to be more protective than either alone.
Diet matters, and so does what you’re not eating
The shift toward visceral fat accumulation in perimenopause is driven partly by declining estrogen and partly by the way the liver and fat tissue handle energy differently without it. A diet that emphasizes whole foods, limits refined carbohydrates and added sugars, prioritizes fiber, omega-3 fatty acids, and high-quality protein, and limits ultra-processed foods is consistently associated with lower cardiovascular risk. The Mediterranean dietary pattern has the most robust evidence in this population specifically.
What reduces visceral fat is not calorie restriction alone. It’s the combination of dietary quality, resistance training, aerobic conditioning, and, where appropriate, addressing the underlying hormonal environment.
Know your real numbers
Beyond the standard lipid panel, the following markers are worth knowing during perimenopause: hsCRP (a marker of vascular inflammation), fasting insulin and HOMA-IR (measures of insulin resistance), the TG:HDL ratio (a proxy for small dense LDL and insulin resistance), blood pressure trends over time, and HbA1c. These are not exotic tests. They are available through standard laboratory work and provide a far more accurate picture of where your cardiovascular risk actually stands.
TG:HDL ratio= Fasting Triglicerides/HDL cholesterol
Optimal is equal to or <1
Low Risk: 2
Moderate/Slight Risk: 3
High Risk: equal to or >4
The hormone therapy conversation
The relationship between hormone therapy and heart disease is more nuanced than most women have been told, and the story changed significantly after a reassessment of the Women’s Health Initiative data.
The WHI, which generated widespread fear about hormone therapy in the early 2000s, enrolled women with an average age of 63, most of them more than a decade past menopause. The timing matters. Research now strongly supports what’s called the timing hypothesis: hormone therapy initiated early in the menopausal transition, within approximately ten years of the final menstrual period or before age 60, appears to have cardiovascular-neutral to cardiovascular-protective effects in healthy women. A 2022 paper in Cancer Journal from USC summarized the evidence: hormone therapy initiated at the time of menopause, in healthy women without pre-existing cardiovascular disease, is associated with reduced all-cause mortality and cardiovascular events. The protective effect is not seen when therapy is started a decade or more after menopause, which is what the WHI largely studied.
The KEEPS trial (Kronos Early Estrogen Prevention Study), which followed women randomized to hormone therapy within three years of menopause, found no increase in cardiovascular risk and demonstrated differential effects on arterial plaque depending on formulation and route of administration. The data support an individualized, timing-sensitive approach to this decision.
Hormone therapy is not the right choice for every woman. There are contraindications, and the decision requires a full clinical picture. But the reflexive avoidance of hormone therapy based on a misreading of the WHI has caused real harm, including denying women a treatment that, for many, would have protected both their hearts and their quality of life during the transition. This is a conversation that deserves more nuance than it usually gets.
The Bottom Line
Heart disease is not something that happens to women later in life as a passive consequence of aging. The vascular changes that lead to it begin during perimenopause, driven by a hormonal shift that has direct, measurable effects on the cardiovascular system. Those changes are often happening quietly, without symptoms, while attention is focused elsewhere.
Knowing this earlier gives you the ability to act earlier. The lifestyle interventions that protect cardiovascular health, exercise, dietary quality, metabolic monitoring, are more effective when started before significant damage has accumulated. The window of perimenopause is also the window where hormonal support, if appropriate, has its greatest protective leverage.
Your heart is not an afterthought in this stage of life. It may be the most important thing worth paying attention to.
All clinical information is drawn from peer-reviewed research.
Hodis HN, Mack WJ. Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It’s About Time and Timing. Cancer Journal. 2022;28(3):208–223. [USC Keck School of Medicine; Framingham data on 10- and 20-year CHD lag; 2–6x postmenopausal risk increase.]
El Khoudary SR, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention. AHA Scientific Statement. Circulation. 2020;142(25):e506–e532.
Ryczkowska K, et al. Menopause and Women’s Cardiovascular Health: Is It Really an Obvious Relationship? Archives of Medical Science. 2023;19(2):458–466. [FSH and cholesterol production; lipid changes independent of estrogen.]
PMC/Frontiers. Cardiovascular Health During Menopause Transition: The Role of Traditional and Nontraditional Risk Factors. 2025. [Perimenopause as pivotal CVD phase; endothelial dysfunction, oxidative stress, hypertension precursors.]
SWAN Heart Study. Lipids, Menopause and Early Atherosclerosis in SWAN Heart Women. PMC/various publications. [Longitudinal lipid and vascular changes through menopausal transition; HDL protective effect weakened post-menopause.]
Aging Women and Their Endothelium: Probing the Relative Role of Estrogen on Vasodilator Function. American Journal of Physiology — Heart and Circulatory Physiology. 2018. [1,054-woman prospective trial; total cholesterol, LDL, ApoB rise at final menstrual period.]
Agency for Healthcare Research and Quality / MedStar Health Research Institute. Women Nearly Twice as Likely as Men to Receive Incorrect Heart Attack Diagnosis. [Women under 55 seven times more likely to be sent home without cardiac testing.]
Brush JE Jr, et al. Sex Differences in Symptom Phenotypes Among Patients With Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes. 2020.
Arber S, McKinlay J, et al. Disparities in Physicians’ Interpretations of Heart Disease Symptoms by Patient Gender. Journal of General Internal Medicine. 2006. [128 physicians; identical symptoms attributed to GI/mental health more often in women; 2x mental health diagnosis rate.]
Bjornson E, et al. Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An ApoB-Based Genetic Analysis. Journal of the American College of Cardiology. 2024;83(3):385–395.
Manson JE, et al. Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long? Circulation. 2023;147(7):597–610.
Harman SM, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric. 2005. [Early HRT initiation; cardiovascular neutrality; differential plaque effects by formulation.]
Brinton LA, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. New England Journal of Medicine. 2016. [Timing hypothesis clinical trial support.]